

Form PTO-1595 (Rev. 07/05)  
OMB No. 0851-0027 (exp. 6/30/2006)

U.S. DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office

# RECORDATION FORM COVER SHEET

## PATENTS ONLY

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

|   |  |  |  |
|---|--|--|--|
| <b>1. Name of conveying party(ies):</b><br>Hybridon Inc.<br>345 Vassar Street<br>Cambridge, Massachusetts 02139-4818<br>Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No  |  | <b>2. Name and address of receiving party(ies)</b><br>Name: <u>Idera Pharmaceuticals, Inc.</u><br>Internal Address: <u>(A Delaware Corporation)</u><br>Street Address:<br>345 Vassar Street<br>City: <u>Cambridge</u><br>State: <u>MA</u><br>Country: <u>USA</u> Zip: <u>02139-4818</u><br>Additional name(s) & address(es) attached: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No                |  |
| <b>3. Nature of conveyance/Execution Date(s):</b><br>Execution Date(s): <u>September 12, 2005</u><br><input type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Change of Name<br><input type="checkbox"/> Security Agreement <input type="checkbox"/> Joint Research Agreement<br><input type="checkbox"/> Government Interest Assignment<br><input type="checkbox"/> Executive Order 9424, Confirmatory License<br><input checked="" type="checkbox"/> Other <u>Certificate of Ownership and Merger</u> |  |  |  |
| <b>4. Application or patent number(s):</b><br>A. Patent Application No.(s)<br>See Attached Table of Patents/Applications<br>Additional numbers attached? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No  |  | <input type="checkbox"/> This document is being filed together with a new application.<br>B. Patent No.(s)<br>See Attached Table of Patents/Applications<br><input checked="" type="checkbox"/> Yes <input type="checkbox"/> No  |  |
| <b>5. Name and address to whom correspondence concerning document should be mailed:</b><br>Name: <u>ANN-LOUISE KERNER, PH.D.</u><br><u>WILMER CUTLER PICKERING HALE AND DORR LLP</u><br>Internal Address: <u>Atty. Dkt.: 47508.475</u><br>Street Address: <u>60 State Street</u><br>City: <u>Boston</u><br>State: <u>MA</u> Zip: <u>02109</u><br>Phone Number: <u>(617) 526-6000</u><br>Fax Number: <u>(617) 526-5000</u><br>Email Address:   |  | <b>6. Total number of applications and patents involved:</b> <u>74</u><br><b>7. Total fee (37 CFR 1.21(h) &amp; 3.41) \$</b> <u>2960</u><br><input type="checkbox"/> Authorized to be charged by credit card<br><input checked="" type="checkbox"/> Authorized to be charged to deposit account<br><input type="checkbox"/> Enclosed<br><input type="checkbox"/> None required (government interest not affecting title) |  |
|   |  | <b>8. Payment Information</b><br>a. Credit Card Last 4 Numbers _____<br>Expiration Date _____<br>b. Deposit Account Number <u>08-0219</u><br>Authorized User Name <u>Ann-Louise Kerner, Ph.D.</u>  |  |
| <b>9. Signature:</b><br><u>Ann-Louise Kerner</u><br>Signature<br><u>Ann-Louise Kerner, Ph.D.</u><br>Name of Person Signing<br>September 28, 2005<br>Date<br>Total number of pages including cover sheet, attachments, and documents: <u>14</u>  |  |  |  |

CH \$2960.00 080219 08098945

## TABLE OF PATENTS/APPLICATIONS

| Appl. No.  | Patent No. | HYBN No.   | Atty Docket No.              |
|------------|------------|------------|------------------------------|
|            | 5,510,475  | 100.0 USC1 | 47508.487 HYZ-487            |
|            | 5,929,226  | 116.0 USC1 | 47508.511 US2 HYZ-511CN      |
|            | 5,684,147  | 120.0 USC1 | 47508.510 HYZ-510CN          |
|            | 5,739,308  | 123.0 USC2 | 47508.500 HYZ-500CN2         |
|            | 5,558,992  | 124.0 USC1 | 4708.503 HYZ-503CN1          |
|            | 5,693,466  | 124.1 USC1 | 47508.503 HYZ-503CN2         |
| 08/098,945 |            | 128.0 US   | 47508.498 HYZ-498            |
|            | 5,670,634  | 129.0 USC1 | 47508.619 HYZ-619CN2         |
|            | 6,410,322  | 131.0 US   | 47508.494US1 HYZ-494         |
|            | 6,489,464  | 132.0 USC1 | 47508.557US4 HYZ-488         |
|            | 5,833,944  | 141.0 US   | 47508.504US1 HYZ-504         |
|            | 5,847,104  | 146.0 US   | 47508.506US1 HYZ-506         |
|            | 5,668,262  | 146.0 USD2 | 47508.506 HYZ-506DV          |
|            | 5,631,361  | 148.0 US   | 47508.491                    |
|            | 5,693,773  | 151.0 US   | 47508.507US1 HYZ-507         |
|            | 5,750,674  | 152.0 US   | 47508.583 / 47508.505        |
|            | 6,117,993  | 152.0 USC1 | 47508.499 HYZ-498/HYZ-564US7 |
|            | 5,506,103  | 158.0 USC  | 47508.653 HYZ-010US          |
|            | 5,637,464  | 159.0 USC1 | 47508.662 HYZ-011CN          |
|            | 5,691,316  | 167.1 US   | 47508.113 HYZ-019CIP         |
|            | 5,616,565  | 167.1USD1  | 47508.114 HYZ-019CPDV1       |
|            | 5,605,890  | 167.1USD2  | 47508.115 HYZ-019CPDV2       |
|            | 5,801,235  | 168.0 US   | 47508.120 HYZ-020            |
|            | 5,866,699  | 170.0 US   | 47508.131 HYZ-022            |
|            | 5,700,923  | 171.0 US   | 47508.137 HYZ-023            |
|            | 5,627,055  | 171.0 USD1 | 47508.138 HYZ-023DV1         |
|            | 5,646,021  | 171.0 USD2 | 47508.139 HYZ-023DV2         |
|            | 5,679,554  | 171.0 USD3 | 47508.140 HYZ-023DV3         |
|            | 5,650,502  | 172.0 US   | 47508.143 HYZ-024            |
|            | 5,679,555  | 172.0 USD3 | 47508.146 HYZ-024DV3         |
|            | 6,372,427  | 175.0 US   | 47508.157 HYZ-027CPA         |
| 10/054,429 |            | 175.2 US   | 47508.580US4 HYZ-027CIP2     |
|            | 5,591,721  | 178.0 US   | 47508.217 HYZ-030            |
|            | 6,645,943  | 178.1 USC1 | 47508.437 HYZ-030CIPCN       |
|            | 6,608,035  | 178.4 US   | 47508.734 HYZ-030CPCN2       |
| 10/640,898 |            | 178.4 USD2 | 47508.751 HYZ-030CPCN2DV2    |
| 09/777,526 |            | 178.5 US   | 47508.518US8 HYZ-030CPCN3    |
|            | 5,545,729  | 180.0 US   | 47508.234 HYZ-032            |
|            | 5,872,007  | 187.0 USD2 | 47508.181 HYZ-039DV2         |
|            | 5,789,248  | 187.1 US   | 47508.178 HYZ-039CIP         |
|            | 5,877,308  | 187.1 USD1 | 47508.179 HYZ-039CPDV        |
| 08/887,505 |            | 188.2 US   | 47508.250US3 HYZ-040CIP      |
|            | 5,968,909  | 191.0 US   | 47508.197 HYZ-043            |

| Appln. No. | Patent No. | HYBN No.   | Atty Docket No.             |
|------------|------------|------------|-----------------------------|
|            | 6,667,293  | 193.0 US   | 47508.201 HYZ-045           |
|            | 5,969,117  | 196.0 US   | 47508.210 HYZ-050           |
|            | 6,624,293  | 196.1 US   | 47508.544 HYZ-050CP1        |
| 10/641,521 |            | 196.1 USD1 | 47508.766US9 HYZ-050CPDV    |
| 09/412,947 |            | 196.2 US   | 47508.446 HYZ-050CP2        |
| 10/854,989 |            | 196.3 US   | 47508.764 HYZ-050CP3        |
|            | 5,793,136  | 198.1 US   | 47508.392                   |
|            | 5,773,601  | 198.2 US   | 47508.391 HYZ-050USCN2      |
|            | 6,140,482  | 199.0 US   | 47508.562US5 HYZ-564        |
|            | 5,614,622  | 200.0 US   | 47508.564US10 HYZ-564US2    |
|            | 6,531,589  | 200.1 US   | 47508.628 HYZ-628           |
|            | 6,440,660  | 207.1 US   | 47508.253 HYZ-047CIP        |
|            | 5,962,674  | 214.0 US   | 47508.629US4 HYZ-564        |
|            | 6,509,459  | 214.2 US   | 47508.338US6 HYZ-564        |
|            | 5,912,332  | 221.0 US   | 47508.519 96,760            |
|            | 6,335,436  | 222.1 US   | 47508.438 HYZ-438US2        |
|            | 6,117,992  | 224.0 USC1 | 47508.641 HYZ-641           |
|            | 5,886,165  | 226.0 US   | 47508.509US1 HYZ-509 96,896 |
|            | 5,856,462  | 227.0 US   | 47508.642 HYZ-642           |
| 09/103,745 |            | 227.1 US   | 47508.642US2 CIP            |
| 08/846,417 |            | 232.1 US   | 47508.603 HYZ-067CPA        |
|            | 6,489,304  | 241.0 US   | 47508.337US2 HYZ-337        |
| 10/265,590 |            | 241.0 USC1 | 47508.609US3 HYZ-337CN1     |
| 09/837,806 |            | 252.0 USC1 | 47508.530 HYZ-069CN         |
| 09/896,692 |            | 252.0 USC2 | 47508.556US3 HYZ-069CN2     |
| 09/283,431 |            | 259.0 US   | 47508.423US2 HYZ-423        |
| 10/291,058 |            | 259.0 USC1 | 47508.752US3 HYZ-078CN      |
| 09/708,786 |            | 261.0 US   | 47508.700US                 |
| 09/845,623 |            | 261.1 US   | 47508.528US2                |
| 10/140,228 |            | 268.0 US   | 47508.587 HYZ-076US         |
| 10/253,132 |            | 272.0 US   | 47508.614US2 HYZ-077        |

09/15/2005 THU 12:18 FAX

02/013

**CERTIFICATE OF OWNERSHIP AND MERGER****MERGING****IDERA PHARMACEUTICALS, INC.**  
(a Delaware corporation)**INTO****HYBRIDON, INC.**  
(a Delaware corporation)

Pursuant to Section 253 of the General Corporation Law of the State of Delaware, Hybridon, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the "Corporation"), does hereby certify:

**FIRST:** That the Corporation was incorporated on May 25, 1989, pursuant to the General Corporation Law of the State of Delaware.

**SECOND:** That the Corporation owns all of the outstanding shares of the capital stock of Idera Pharmaceuticals, Inc., a corporation incorporated on August 24, 2005, pursuant to the General Corporation Law of the State of Delaware (the "Subsidiary").

**THIRD:** That on September 9, 2005, the Board of Directors of the Corporation, acting by written consent in accordance with Section 141(f) of the General Corporation Law of the State of Delaware, duly adopted the following resolutions and determined to merge the Subsidiary into the Corporation and change the Corporation's corporate name to "Idera Pharmaceuticals, Inc." on the conditions set forth in such resolutions:

**RESOLVED:** That, the Corporation shall, pursuant to Section 253 of the Delaware Code, merge into itself Idera Pharmaceuticals, Inc., a wholly owned subsidiary of the Corporation (the "Subsidiary"), and shall assume all of the Subsidiary's liabilities and obligations (the "Merger"); and that upon the effectiveness of the Merger, the Corporation's corporate name shall be changed to "Idera Pharmaceuticals, Inc."

**RESOLVED:** That the Corporation, as the sole stockholder of the Subsidiary, be and hereby is authorized to take such actions as are necessary or appropriate to effect the Merger.

09/15/2005 THU 12:18 FAX

003/013

RESOLVED: That the Chief Executive Officer and the Chief Financial Officer of the Corporation (the "Proper Officers") be, and either acting singly, hereby is authorized and directed in the name and on behalf of the Corporation to prepare, execute and file with the Secretary of State of the State of Delaware a Certificate of Ownership and Merger setting forth a copy of the resolutions to merge the Subsidiary into the Corporation and to assume the liabilities and obligations of said Subsidiary and to change the Corporation's corporate name to "Idera Pharmaceuticals, Inc." upon the effectiveness of the Merger; and that the execution and filing thereof be conclusive evidence of such approval and the authorization therefor by the Board of Directors of the Corporation.

**FOURTH:** That the Merger of Subsidiary into the Corporation be effective as of September 12, 2005 at 4:01 p.m. (ET).

IN WITNESS WHEREOF, the Corporation has caused this Certificate to be signed by its authorized officer this 12<sup>th</sup> day of September, 2005.

HYBRIDON, INC.

By: 

Name: Sudhir Agrawal

Title: Chief Executive Officer and  
President

09/15/2005 THU 12:18 FAX

04/013

**HYBRIDON, INC.****Action by Unanimous Written Consent of Directors in Lieu of a Meeting**

September 9, 2005

The undersigned, being all of the members of the Board of Directors (the "Board") of Hybridon, Inc., a Delaware corporation (the "Corporation"), and acting in accordance with Section 141(f) of the Delaware General Corporation Law, hereby consent to the adoption of the following resolutions:

**I Merger with Subsidiary**

RESOLVED: That, the Corporation shall, pursuant to Section 253 of the Delaware Code, merge into itself Idera Pharmaceuticals, Inc., a wholly owned subsidiary of the Corporation (the "Subsidiary"), and shall assume all of the Subsidiary's liabilities and obligations (the "Merger"); and that upon the effectiveness of the Merger, the Corporation's corporate name shall be changed to "Idera Pharmaceuticals, Inc."

RESOLVED: That the Corporation, as the sole stockholder of the Subsidiary, be and hereby is authorized to take such actions as are necessary or appropriate to effect the Merger.

RESOLVED: That the Chief Executive Officer and the Chief Financial Officer of the Corporation (the "Proper Officers") be, and either acting singly, hereby is authorized and directed in the name and on behalf of the Corporation to prepare, execute and file with the Secretary of State of the State of Delaware a Certificate of Ownership and Merger setting forth a copy of the resolutions to merge the Subsidiary into the Corporation and to assume the liabilities and obligations of said Subsidiary and to change the Corporation's corporate name to "Idera Pharmaceuticals, Inc." upon the effectiveness of the Merger; and that the execution and filing thereof be conclusive evidence of such approval and the authorization therefor by the Board of Directors of the Corporation.

**II General Authority**

RESOLVED: That the Proper Officers of the Corporation be, and either acting singly hereby is, authorized and directed, in the name and on behalf of the Corporation, to execute and deliver all agreements, instruments, documents and certificates, and to take all such actions in connection therewith as such officer shall determine, in his sole discretion, to be necessary, appropriate or desirable in order to carry out the purposes of the foregoing resolution; and that the execution and delivery of any such instruments, agreements, documents and certificates and the taking of any such other action by such officer shall be conclusive evidence of such determination and approval and of the due authorization and approval of the Board.

09/15/2005 THU 12:19 FAX

0006/013

09/02/2005 FRI 09:13 FAX

0003/003

IN WITNESS WHEREOF, the undersigned have executed in counterpart this Unanimous  
Written Consent of Directors in Lieu of a Meeting as of the date first written above.

James B. Wyngaarden  
James B. Wyngaarden, M.D.

Sudhir Agrawal, D. Phil

Youssef El-Zein

C. Keith Hartley

Robert W. Karr, M.D.

William B. Wanda, C.D.A.

Alison Taunton-Rigby, Ph.D., OBE


Paul C. Zamecnik, M.D.

09/15/2005 THU 12:19 FAX

007/013

IN WITNESS WHEREOF, the undersigned have executed in counterpart this Unanimous Written Consent of Directors in Lieu of a Meeting as of the date first written above.

\_\_\_\_\_  
James B. Wyngaarden, M.D.

  
\_\_\_\_\_  
Sudhir Agrawal, D. Phil

\_\_\_\_\_  
Youssef El-Zein

\_\_\_\_\_  
C. Keith Hartley

\_\_\_\_\_  
Robert W. Karr, M.D.

\_\_\_\_\_  
William S. Reardon, C.P.A.

\_\_\_\_\_  
Alison Taunton-Rigby, Ph.D., OBE

\_\_\_\_\_  
Paul C. Zamecnik, M.D.



09/15/2005 THU 12:19 FAX

008/013

IN WITNESS WHEREOF, the undersigned have executed in counterpart this Unanimous  
Written Consent of Directors in Lieu of a Meeting as of the date first written above.

James B. Wyngaarden, M.D.

Sedhir Agrawal, D. Phil

Youssef El-Zein

C. Keith Hartley

Robert W. Karr, M.D.

William S. Reardon, C.P.A.

Alison Taunton-Rigby, Ph.D., OBE

Paul C. Zamecnik, M.D.

USDOC 3721472

- 2 -

09/15/2005 THU 12:18 FAX

09/013  
272

IN WITNESS WHEREOF, the undersigned have executed in counterpart this Unanimous Written Consent of Directors in Lieu of a Meeting as of the date first written above.

James B. Wyngaarden, M.D.

Sudhir Agrawal, D. Phil

Youssef El-Zein

  
C. Keith Hartley

Robert W. Karr, M.D.

William S. Reardon, C.P.A.

Alison Taunton-Rigby, Ph.D., OBE

Paul C. Zamecnik, M.D.

09/15/2005 THU 12:19 FAX

010/013

IN WITNESS WHEREOF, the undersigned have executed in counterpart this Unanimous  
Written Consent of Directors in Lieu of a Meeting as of the date first written above.

\_\_\_\_\_  
James B. Wyngaarden, M.D.

\_\_\_\_\_  
Sudhir Agrawal, D. Phil

\_\_\_\_\_  
Youssef El-Zein

\_\_\_\_\_  
C. Keith Hartley

\_\_\_\_\_  
*Robert W. Karr*  
Robert W. Karr, M.D.

\_\_\_\_\_  
William S. Reardon, C.P.A.

\_\_\_\_\_  
Alison Taunton-Rigby, Ph.D., OBE

\_\_\_\_\_  
Paul C. Zamecnik, M.D.

09/15/2005 THU 12:20 FAX

011/013

IN WITNESS WHEREOF, the undersigned have executed in counterpart this Unanimous  
Written Consent of Directors in Lieu of a Meeting as of the date first written above.

James B. Wyngaarden, M.D.

Sudhir Agrawal, D. Phil

Youssef El-Zein

C. Keith Hartley

Robert W. Karr, M.D.

*William S. Reardon*  
William S. Reardon, C.P.A.

Alison Taunton-Rigby, Ph.D., OBE

Paul C. Zamecnik, M.D.

09/15/2005 THU 12:20 FAX

012/013

IN WITNESS WHEREOF, the undersigned have executed in counterpart this Unanimous  
Written Consent of Directors in Lieu of a Meeting as of the date first written above.

James B. Wyngaarden, M.D.

Sudhir Agrawal, D. Phil

Youssef El-Zein

C. Keith Hartley

Robert W. Karr, M.D.

William S. Reardon, C.P.A.

  
Alison Taunton-Rigby, Ph.D., OBE

Paul C. Zamecnik, M.D.

09/15/2005 THU 12:20 FAX

013/013

IN WITNESS WHEREOF, the undersigned have executed in counterpart this Unanimous Written Consent of Directors in Lieu of a Meeting as of the date first written above.

James B. Wyngaarden, M.D.

Sudhir Agrawal, D. Phil

Youssef El-Zein

C. Keith Hartley

Robert W. Karr, M.D.

William S. Reardon, C.P.A.

Alison Taunton-Rigby, Ph.D., OBE

*Paul C. Zamecnik*

Paul C. Zamecnik, M.D.

9/16/05